Valneva initiates phase I/II clinical trial in UK of its inactivated and adjuvanted COVID-19 vaccine, VLA2001

The study will be conducted in four study sites across the UK. The company expects primary endpoint read-out to be ready 2 weeks after completion of 2-dose primary immunisation (day 0,28). Selection of optimal dose currently expected in early second quarter of 2021.

PharmaTimes